Molecular Determinants of Dofetilide Block of HERG K⁺ Channels

From the Rammelkamp Center for Education and Research (E.F., A.M.B.), MetroHealth Campus, Case Western Reserve University, School of Medicine, Cleveland, Ohio; the Institut für Biologische Informationsverarbeitung (A.B.), Forschungszentrum Jülich (Germany); Physiologisches Institut (W.J.), Heidelberg, Germany; and Kardiologie (J.K.), Universitätsklinik Heidelberg (Germany).

Correspondence to Dr Eckhard Ficker, Rammelkamp Center for Education and Research, MetroHealth Medical Center, 2500 MetroHealth Dr, Cleveland, OH 44109-1998. E-mail eficker{at}research.mhmc.org

Abstract—The human ether-a-go-go–related gene (HERG) encodes a K⁺ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K⁺ current (I_Kr). HERG/I_Kr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations. By contrast, the closely related bovine ether-a-go-go channel (BEAG) is 100-fold less sensitive to dofetilide. To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and BEAG and then used site-directed mutagenesis to localize single amino acid residues responsible for block. Using constructs heterologously expressed in Xenopus oocytes, we found that transplantation of the S5-S6 linker from BEAG into HERG removed high-affinity block by dofetilide. A point mutation in the S5-S6 linker region, HERG S620T, abolished high-affinity block and interfered with C-type inactivation. Thus, our results indicate that important determinants of dofetilide binding are localized to the pore region of HERG. Since the loss of high-affinity drug binding was always correlated with a loss of C-type inactivation, it is possible that the changes observed in drug binding are due to indirect allosteric modifications in the structure of the channel protein and not to the direct interaction of dofetilide with the respective mutated site chains. However, the chimeric approach was not able to identify domains outside the S5-S6 linker region of the HERG channel as putative candidates involved in drug binding. Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG K⁺ channels for dofetilide, whereas C-type inactivation could not be recovered. Thus, the serine in position HERG 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.

Key Words: human ether-a-go-go–related gene • bovine ether-a-go-go channel • K⁺ channel • antiarrhythmic drug • dofetilide

This article has been cited by other articles:

				S. Z. Stepanovic, F. Potet, C. I. Petersen, J. A. Smith, J. Meiler, J. R. Balser, and S. Kupershmidt The evolutionarily conserved residue A653 plays a key role in HERG channel closing J. Physiol., June 1, 2009; 587(11): 2555 - 2566. [Abstract] [Full Text] [PDF]

				S. B. Ganapathi, M. Kester, and K. S. Elmslie State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy Am J Physiol Cell Physiol, April 1, 2009; 296(4): C701 - C710. [Abstract] [Full Text] [PDF]

				M. J. Perrin, P. W. Kuchel, T. J. Campbell, and J. I. Vandenberg Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-a-go-go-Related Gene Channels Mol. Pharmacol., November 1, 2008; 74(5): 1443 - 1452. [Abstract] [Full Text] [PDF]

				H. Sale, J. Wang, T. J. O'Hara, D. J. Tester, P. Phartiyal, J.-Q. He, Y. Rudy, M. J. Ackerman, and G. A. Robertson Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome Circ. Res., September 26, 2008; 103(7): e81 - e95. [Abstract] [Full Text] [PDF]

				T. Luo, A. Luo, M. Liu, and X. Liu Inhibition of the HERG Channel by Droperidol Depends on Channel Gating and Involves the S6 Residue F656 Anesth. Analg., April 1, 2008; 106(4): 1161 - 1170. [Abstract] [Full Text] [PDF]

				M. Perry, F. B. Sachse, and M. C. Sanguinetti Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator PNAS, August 21, 2007; 104(34): 13827 - 13832. [Abstract] [Full Text] [PDF]

				S. Y. M. Yeung and I. A. Greenwood Pharmacological and biophysical isolation of K+ currents encoded by ether-a-go-go-related genes in murine hepatic portal vein smooth muscle cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C468 - C476. [Abstract] [Full Text] [PDF]

				J. I. Vandenberg, A. P. Hill, T. J. Campbell, and C. E. Clarke Reply from Jamie I. Vandenberg, Adam P. Hill, Terence J. Campbell, Catherine E. Clarke J. Physiol., November 15, 2006; 577(1): 461 - 462. [Full Text] [PDF]

				J. I. Vandenberg, A. Varghese, Y. Lu, J. A. Bursill, M. P. Mahaut-Smith, and C. L.-H. Huang Temperature dependence of human ether-a-go-go-related gene K+ currents Am J Physiol Cell Physiol, July 1, 2006; 291(1): C165 - C175. [Abstract] [Full Text] [PDF]

				C. E. Clarke, A. P. Hill, J. Zhao, M. Kondo, R. N. Subbiah, T. J. Campbell, and J. I. Vandenberg Effect of S5P {alpha}-helix charge mutants on inactivation of hERG K+ channels J. Physiol., June 1, 2006; 573(2): 291 - 304. [Abstract] [Full Text] [PDF]

				T. Ferrer, J. Rupp, D. R. Piper, and M. Tristani-Firouzi The S4-S5 Linker Directly Couples Voltage Sensor Movement to the Activation Gate in the Human Ether-a-go-go-related Gene (hERG) K+ Channel J. Biol. Chem., May 5, 2006; 281(18): 12858 - 12864. [Abstract] [Full Text] [PDF]

				J. Guo, H. Gang, and S. Zhang Molecular Determinants of Cocaine Block of Human Ether-a-go-go-Related Gene Potassium Channels J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 865 - 874. [Abstract] [Full Text] [PDF]

				S. Rezazadeh, T. W. Claydon, and D. Fedida KN-93 (2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor, Is a Direct Extracellular Blocker of Voltage-Gated Potassium Channels J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 292 - 299. [Abstract] [Full Text] [PDF]

				R. Brugada, K. Hong, J. M. Cordeiro, and R. Dumaine Short QT syndrome Can. Med. Assoc. J., November 22, 2005; 173(11): 1349 - 1354. [Abstract] [Full Text] [PDF]

				J. Lin, J. Guo, H. Gang, P. Wojciechowski, J. T. Wigle, and S. Zhang Intracellular K+ Is Required for the Inactivation-Induced High-Affinity Binding of Cisapride to HERG Channels Mol. Pharmacol., September 1, 2005; 68(3): 855 - 865. [Abstract] [Full Text] [PDF]

				B. P. Delisle, J. K. Slind, J. A. Kilby, C. L. Anderson, B. D. Anson, R. C. Balijepalli, D. J. Tester, M. J. Ackerman, T. J. Kamp, and C. T. January Intragenic Suppression of Trafficking-Defective KCNH2 Channels Associated with Long QT Syndrome Mol. Pharmacol., July 1, 2005; 68(1): 233 - 240. [Abstract] [Full Text] [PDF]

				C. Lin, X. Ke, I. Cvetanovic, V. Ranade, and J. Somberg The Influence of Extracellular Acidosis on the Effect of IKr Blockers Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 67 - 76. [Abstract] [PDF]

				C. E. Clancy and R. S. Kass Inherited and Acquired Vulnerability to Ventricular Arrhythmias: Cardiac Na+ and K+ Channels Physiol Rev, January 1, 2005; 85(1): 33 - 47. [Abstract] [Full Text] [PDF]

				D. L. Weiss, G. Seemann, F. B. Sachse, and O. Dössel Modelling of short QT syndrome in a heterogeneous model of the human ventricular wall Europace, January 1, 2005; 7(s2): S105 - S117. [Abstract] [Full Text] [PDF]

				S. Rezazadeh, J. C. Hesketh, and D. Fedida Rb+ Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb+ Efflux Assay J Biomol Screen, October 1, 2004; 9(7): 588 - 597. [Abstract] [PDF]

				G. Gessner, M. Zacharias, S. Bechstedt, R. Schonherr, and S. H. Heinemann Molecular Determinants for High-Affinity Block of Human EAG Potassium Channels by Antiarrhythmic Agents Mol. Pharmacol., May 1, 2004; 65(5): 1120 - 1129. [Abstract] [Full Text]

				H. T. Kurata, Z. Wang, and D. Fedida NH2-terminal Inactivation Peptide Binding to C-type-inactivated Kv Channels J. Gen. Physiol., April 26, 2004; 123(5): 505 - 520. [Abstract] [Full Text] [PDF]

				G. C. L. Bett and R. L. Rasmusson Inactivation and recovery in Kv1.4 K+ channels: lipophilic interactions at the intracellular mouth of the pore J. Physiol., April 1, 2004; 556(1): 109 - 120. [Abstract] [Full Text] [PDF]

				R. Brugada, K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, T. M. Menendez, J. Brugada, G. D. Pollevick, C. Wolpert, et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG Circulation, January 6, 2004; 109(1): 30 - 35. [Abstract] [Full Text] [PDF]

				A. M. Torres, P. S. Bansal, M. Sunde, C. E. Clarke, J. A. Bursill, D. J. Smith, A. Bauskin, S. N. Breit, T. J. Campbell, P. F. Alewood, et al. Structure of the HERG K+ Channel S5P Extracellular Linker: ROLE OF AN AMPHIPATHIC {alpha}-HELIX IN C-TYPE INACTIVATION J. Biol. Chem., October 24, 2003; 278(43): 42136 - 42148. [Abstract] [Full Text] [PDF]

				K. J Paavonen, H. Chapman, P. J Laitinen, H. Fodstad, K. Piippo, H. Swan, L. Toivonen, M. Viitasalo, K. Kontula, and M. Pasternack Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG) Cardiovasc Res, September 1, 2003; 59(3): 603 - 611. [Abstract] [Full Text] [PDF]

				X. Jiang, G. C L Bett, X. Li, V. E Bondarenko, and R. L Rasmusson C-Type inactivation involves a significant decrease in the intracellular aqueous pore volume of Kv1.4 K+ channels expressed in Xenopus oocytes J. Physiol., June 15, 2003; 549(3): 683 - 695. [Abstract] [Full Text] [PDF]

				M. Madeja, T. Leicher, P. Friederich, M. A. Punke, W. Haverkamp, U. Musshoff, G. Breithardt, and E.-J. Speckmann Molecular Site of Action of the Antiarrhythmic Drug Propafenone at the Voltage-Operated Potassium Channel Kv2.1 Mol. Pharmacol., March 1, 2003; 63(3): 547 - 556. [Abstract] [Full Text] [PDF]

				K. Ishii, M. Nagai, M. Takahashi, and M. Endoh Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency Cardiovasc Res, March 1, 2003; 57(3): 651 - 659. [Abstract] [Full Text] [PDF]

				C. Arias, T. Gonzalez, I. Moreno, R. Caballero, E. Delpon, J. Tamargo, and C. Valenzuela Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels Cardiovasc Res, March 1, 2003; 57(3): 660 - 669. [Abstract] [Full Text] [PDF]

				S. Wang, M. J Morales, Y.-J. Qu, G. C L Bett, H. C Strauss, and R. L Rasmusson Kv1.4 channel block by quinidine: evidence for a drug-induced allosteric effect J. Physiol., January 15, 2003; 546(2): 387 - 401. [Abstract] [Full Text] [PDF]

				X. Li, G. C. L. Bett, X. Jiang, V. E. Bondarenko, M. J. Morales, and R. L. Rasmusson Regulation of N- and C-type inactivation of Kv1.4 by pHo and K+: evidence for transmembrane communication Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H71 - H80. [Abstract] [Full Text] [PDF]

				A. N. Katchman, K. A. McGroary, M. J. Kilborn, C. A. Kornick, P. L. Manfredi, R. L. Woosley, and S. N. Ebert Influence of Opioid Agonists on Cardiac Human Ether-a-go-go-related Gene K+ Currents J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 688 - 694. [Abstract] [Full Text] [PDF]

				J. Chen, G. Seebohm, and M. C. Sanguinetti Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels PNAS, September 17, 2002; 99(19): 12461 - 12466. [Abstract] [Full Text] [PDF]

				J.-B. Park, H. Choe, Y.-K. Lee, K.-C. Ha, K.-S. Rhee, J.-K. Ko, C.-U. Joo, S.-W. Chae, and Y.-G. Kwak Open Channel Block by KCB-328 [1-(2-Amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane Hydrochloride] of the Heterologously Expressed Human Ether-a-go-go-Related Gene K+ Channels J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 314 - 319. [Abstract] [Full Text] [PDF]

				L. Pardo-Lopez, M. Zhang, J. Liu, M. Jiang, L. D. Possani, and G.-N. Tseng Mapping the Binding Site of a Human ether-a-go-go-related Gene-specific Peptide Toxin (ErgTx) to the Channel's Outer Vestibule J. Biol. Chem., May 3, 2002; 277(19): 16403 - 16411. [Abstract] [Full Text] [PDF]

				A. Pannaccione, P. Castaldo, E. Ficker, L. Annunziato, and M. Taglialatela Histidines 578 and 587 in the S5-S6 Linker of the Human Ether-a-gogo Related Gene-1 K+ Channels Confer Sensitivity to Reactive Oxygen Species J. Biol. Chem., March 8, 2002; 277(11): 8912 - 8919. [Abstract] [Full Text] [PDF]

				D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548. [Abstract] [Full Text] [PDF]

				M. E O'Leary Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol Cardiovasc Res, January 1, 2002; 53(1): 59 - 67. [Abstract] [Full Text] [PDF]

				E. Ficker, W. Jarolimek, and A. M. Brown Molecular Determinants of Inactivation and Dofetilide Block in ether a-go-go (EAG) Channels and EAG-Related K+ Channels Mol. Pharmacol., December 1, 2001; 60(6): 1343 - 1348. [Abstract] [Full Text] [PDF]

				W. Tang, J. Kang, X. Wu, D. Rampe, L. Wang, H. Shen, Z. Li, D. Dunnington, and T. Garyantes Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel J Biomol Screen, October 1, 2001; 6(5): 325 - 331. [Abstract] [PDF]

				A.E. Lacerda, J. Kramer, K.-Z. Shen, D. Thomas, and A.M. Brown Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K23 - K30. [Abstract] [PDF]

				E. Schulze-Bahr, W. Haverkamp, L. Eckardt, P. Kirchhof, H. Wedekind, and G. Breithardt Genetic aspects in acquired long QT syndrome -- a piece in the puzzle Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K48 - K52. [Abstract] [PDF]

				I. Cavero and W. Crumb Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K53 - K63. [Abstract] [PDF]

				K. Kamiya, J. S. Mitcheson, K. Yasui, I. Kodama, and M. C. Sanguinetti Open Channel Block of HERG K+ Channels by Vesnarinone Mol. Pharmacol., August 1, 2001; 60(2): 244 - 253. [Abstract] [Full Text] [PDF]

				C. E. Clancy and Y. Rudy Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death Cardiovasc Res, May 1, 2001; 50(2): 301 - 313. [Abstract] [Full Text] [PDF]

				G. Lande, S. Demolombe, A. Bammert, A. Moorman, F. Charpentier, and D. Escande Transgenic mice overexpressing human KvLQT1 dominant-negative isoform Part II: Pharmacological profile Cardiovasc Res, May 1, 2001; 50(2): 328 - 334. [Abstract] [Full Text] [PDF]

				S. Zhang, S. Rajamani, Y. Chen, Q. Gong, Y. Rong, Z. Zhou, A. Ruoho, and C. T. January Cocaine Blocks HERG, but Not KvLQT1+minK, Potassium Channels Mol. Pharmacol., April 16, 2001; 59(5): 1069 - 1076. [Abstract] [Full Text]

				T. González, M. Longobardo, R. Caballero, E. Delpón, J. Tamargo, and C. Valenzuela Effects of Bupivacaine and a Novel Local Anesthetic, IQB-9302, on Human Cardiac K+ Channels J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 573 - 583. [Abstract] [Full Text]

				D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872 J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761. [Abstract] [Full Text]

				M. E. O'Leary Inhibition of Human Ether-A-Go-Go Potassium Channels by Cocaine Mol. Pharmacol., February 1, 2001; 59(2): 269 - 277. [Abstract] [Full Text]

				C. A Karle, V. A.W Kreye, D. Thomas, K. Rockl, S. Kathofer, W. Zhang, and J. Kiehn Antiarrhythmic drug carvedilol inhibits HERG potassium channels Cardiovasc Res, February 1, 2001; 49(2): 361 - 370. [Abstract] [Full Text] [PDF]

				H. Numaguchi, F. M. Mullins, J. P. Johnson Jr., D. C. Johns, S. S. Po, I. C.-H. Yang, G. F. Tomaselli, and J. R. Balser Probing the Interaction Between Inactivation Gating and Dd-Sotalol Block of HERG Circ. Res., November 24, 2000; 87(11): 1012 - 1018. [Abstract] [Full Text] [PDF]

				E. Ficker, D. Thomas, P. C. Viswanathan, A. T. Dennis, S. G. Priori, C. Napolitano, M. Memmi, B. A. Wible, E. S. Kaufman, S. Iyengar, et al. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1748 - H1756. [Abstract] [Full Text] [PDF]

				J. S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M. C. Sanguinetti A structural basis for drug-induced long QT syndrome PNAS, September 22, 2000; (2000) 210244497. [Abstract] [Full Text]

				M. Weerapura, S. Nattel, M. Courtemanche, D. Doern, N. Ethier, and T. E Hebert State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes J. Physiol., July 15, 2000; 526(2): 265 - 278. [Abstract] [Full Text] [PDF]

				J. L. Overholt, E. Ficker, T. Yang, H. Shams, G. R. Bright, and N. R. Prabhakar HERG-Like Potassium Current Regulates the Resting Membrane Potential in Glomus Cells of the Rabbit Carotid Body J Neurophysiol, March 1, 2000; 83(3): 1150 - 1157. [Abstract] [Full Text] [PDF]

				J. P. Lees-Miller, Y. Duan, G. Q. Teng, and H. J. Duff Molecular Determinant of High-Affinity Dofetilide Binding to HERG1 Expressed in Xenopus Oocytes: Involvement of S6 Sites Mol. Pharmacol., February 1, 2000; 57(2): 367 - 374. [Abstract] [Full Text]

				B M Heath and D A Terrar Protein kinase C enhances the rapidly activating delayed rectifier potassium current, IKr, through a reduction in C-type inactivation in guinea-pig ventricular myocytes J. Physiol., February 1, 2000; 522(3): 391 - 402. [Abstract] [Full Text] [PDF]

				W. J. Crumb Jr. Loratadine Blockade of K+ Channels in Human Heart: Comparison with Terfenadine under Physiological Conditions J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 261 - 264. [Abstract] [Full Text]

				D. M Roden and J. R Balser A plethora of mechanisms in the HERG-related long QT syndrome: Genetics meets electrophysiology Cardiovasc Res, November 1, 1999; 44(2): 242 - 246. [Full Text] [PDF]

				H.-Z. Wang, H. Shi, S.-J. Liao, and Z. Wang Inactivation gating determines nicotine blockade of human HERG channels Am J Physiol Heart Circ Physiol, September 1, 1999; 277(3): H1081 - H1088. [Abstract] [Full Text] [PDF]

				S. Zhang, Z. Zhou, Q. Gong, J. C. Makielski, and C. T. January Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels Circ. Res., May 14, 1999; 84(9): 989 - 998. [Abstract] [Full Text] [PDF]

				M. C. Trudeau, S. A. Titus, J. L. Branchaw, B. Ganetzky, and G. A. Robertson Functional Analysis of a Mouse Brain Elk-Type K+ Channel J. Neurosci., April 15, 1999; 19(8): 2906 - 2918. [Abstract] [Full Text] [PDF]

				T. Nakajima, T. Furukawa, T. Tanaka, Y. Katayama, R. Nagai, Y. Nakamura, and M. Hiraoka Novel Mechanism of HERG Current Suppression in LQT2 : Shift in Voltage Dependence of HERG Inactivation Circ. Res., August 24, 1998; 83(4): 415 - 422. [Abstract] [Full Text] [PDF]

				R. L. Rasmusson, M. J. Morales, S. Wang, S. Liu, D. L. Campbell, M. V. Brahmajothi, and H. C. Strauss Inactivation of Voltage-Gated Cardiac K+ Channels Circ. Res., April 20, 1998; 82(7): 739 - 750. [Abstract] [Full Text] [PDF]

				J. S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M. C. Sanguinetti A structural basis for drug-induced long QT syndrome PNAS, October 24, 2000; 97(22): 12329 - 12333. [Abstract] [Full Text] [PDF]